Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
975 stopped studies mapped to Digestive System Carcinoma and descendants · 93% state a reason
Over the 975 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06405061 | Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and… | Phase 2 | suspended | May 8, 2024 | Tianjin Medical University Cancer Institute and Hospital | Mid-term data analysis for the project has been completed; enrollment is now suspended. | Enrollment / accrual |
| NCT04975217 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Early Phase 1 | suspended | Jul 23, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT03825289 | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer(THREAD) | Phase 1 | terminated | Jan 31, 2019 | University of Utah | Lack of Funding | Funding |
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | Phase 2 | terminated | Feb 3, 2022 | National Cancer Institute (NCI) | Protocol has been completed prematurely due to poor accrual and study feasibility. | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT02928627 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in… | — | terminated | Oct 10, 2016 | University of Aberdeen | The project did not progress as there were no findings available for the lab analysis of microRNA… | Other (stated, no rule matched) |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Phase 1 / Phase 2 | suspended | Jan 20, 2022 | University of Chicago | enrollment goal met pending determination of evaluable subjects | Enrollment / accrual |
| NCT06653010 | Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer(Wondercel-UWD1) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT06675513 | Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer | Early Phase 1 | suspended | Nov 5, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed… | Phase 2 | terminated | Aug 30, 2021 | University of Cincinnati | The study is closing due to low enrollment and feasibility of the study. | Enrollment / accrual |
| NCT02908048 | Extracellular RNA Markers of Liver Disease and Cancer | — | terminated | Sep 20, 2016 | Mayo Clinic | Ran out of funds | Funding |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for… | Phase 2 | terminated | Jul 26, 2019 | National Cancer Institute (NCI) | Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment… | Investigator |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | N/A | terminated | Feb 26, 2014 | University Hospital, Rouen | Analysis not possible at the stage | Other (stated, no rule matched) |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or… | Phase 2 | withdrawn | Jul 22, 2020 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04929015 | Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES… | N/A | suspended | Jun 18, 2021 | Rutgers, The State University of New Jersey | Pending Protocol amendment | Other (stated, no rule matched) |
| NCT05718882 | Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC | N/A | terminated | Feb 8, 2023 | RenJi Hospital | The study was terminated because the originally planned VIC-1911 dose-escalation scheme (100 mg,… | Safety / toxicity |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | Phase 2 | terminated | Nov 2, 2021 | Emory University | Slow Accrual | Enrollment / accrual |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers… | Phase 1 / Phase 2 | terminated | May 13, 2020 | University of Southern California | Study drug no longer available | Other (stated, no rule matched) |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and… | Phase 1 / Phase 2 | terminated | Jun 26, 2025 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT02872831 | Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle | N/A | withdrawn | Aug 19, 2016 | Thomas Jefferson University | Principal Investigator let the institution prior to study initiation. | Investigator |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in…(TOGAR) | Phase 2 | terminated | Oct 5, 2022 | Baylor College of Medicine | Since activation, 3 subjects were enrolled but were ineligible for randomization to a treatment arm… | Enrollment / accrual |
| NCT06152523 | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer(MONAMI) | Phase 2 | withdrawn | Nov 30, 2023 | Assistance Publique - Hôpitaux de Paris | The study has been halted because the manufacturer can no longer supply the experimental treatment | Drug supply |
| NCT07511972 | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor… | Phase 2 | withdrawn | Apr 6, 2026 | NGM Biopharmaceuticals, Inc | Study terminated by Sponsor | Other (stated, no rule matched) |
| NCT03727633 | Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial…(LIDA-BII) | Phase 2 | terminated | Nov 1, 2018 | University Hospital, Montpellier | Enrollement rythm low, funding body decision. | Enrollment / accrual |
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating… | Phase 4 | suspended | Feb 19, 2015 | University of Chicago | Pending data analysis | Other (stated, no rule matched) |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05240040 | Treat Primary and Metastatic Liver Tumors | — | withdrawn | Feb 15, 2022 | Methodist Health System | Resources | Other (stated, no rule matched) |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and…(ALAFOSS-01) | Phase 1 | terminated | Sep 19, 2024 | AstraZeneca | The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01… | Enrollment / accrual |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word… | N/A | terminated | May 8, 2015 | Centre Oscar Lambret | Lack of patient enrollment | Enrollment / accrual |
| NCT04166383 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | Phase 2 | terminated | Nov 18, 2019 | National Cancer Institute (NCI) | Interim analysis indicated limited efficacy | Efficacy / futility |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | Phase 3 | terminated | Mar 2, 2021 | Translational Research in Oncology | The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve… | Enrollment / accrual |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With…(MAST) | Phase 1 | terminated | Apr 26, 2022 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT06292975 | Exercise for Improving Radiotherapy Efficacy in Rectal Cancer | N/A | withdrawn | Mar 5, 2024 | University of Hull | Although patients were screened, only two met the eligibility criteria within the available… | Enrollment / accrual |
| NCT04327700 | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | Phase 2 | terminated | Mar 31, 2020 | Wake Forest University Health Sciences | Slow accruals | Enrollment / accrual |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the… | Phase 1 / Phase 2 | terminated | Mar 5, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary… | Phase 2 | terminated | Dec 24, 2018 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT06217094 | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 | withdrawn | Jan 22, 2024 | University of Florida | funding terminated | Funding |
| NCT06851104 | A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With… | Phase 2 | terminated | Feb 28, 2025 | Guangxi Medical University | The support from the relevant company was not obtained as planned | Sponsor / business decision |
| NCT02738606 | Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver… | Phase 2 | terminated | Apr 14, 2016 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With… | Phase 1 / Phase 2 | withdrawn | Apr 5, 2022 | Institut de Recherches Internationales Servier | Strategic development reasons | Sponsor / business decision |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT05360745 | Quality of Life With Nutritional Supplementation in Patients With Locally…(FOODPANC) | N/A | withdrawn | May 4, 2022 | Fundacion para la Excelencia y la Calidad de la Oncologia | Few months later the site initiation visit, the principal investigator decided not to continue with… | Investigator |
| NCT05489250 | The PLATON Network(PLATON) | — | terminated | Aug 5, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sponsor Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 29, 2026source: clinicaltrials